Clinical next generation sequencing to identify actionable aberrations in a phase I program.
Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam F.
Boland GM, et al. Among authors: horombe c.
Oncotarget. 2015 Aug 21;6(24):20099-110. doi: 10.18632/oncotarget.4040.
Oncotarget. 2015.
PMID: 26015395
Free PMC article.
Clinical Trial.